| Name | Title | Contact Details |
|---|
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
Trinity Health - New England is an integrated health care delivery system comprised of world-class providers and facilities dedicated to the full spectrum of preventive, acute, and post-acute care, all delivered with the triple aim of better health, better care, and lower costs for our patient populations. In New England, our hospitals, walk-in clinics, medical offices, specialized facilities, affiliated institutions, and foundations serve a population of nearly 3 million people. As a dynamic part of Trinity Health, based in Livonia, Michigan, and one of the nation`s largest multi-institutional Catholic health care delivery systems, Trinity Health - New England is uniquely positioned to advance health care through alliances with the University of Connecticut School of Medicine, the Frank H. Netter MD School of Medicine at Quinnipiac University, and through our own research institutions dedicated to the development of primary care, new treatments for cancer and MS, and much more.
Keystone Emergency Management Group is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
American Clinical Research Services is a company that provides clinical research services.